Cargando…

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

INTRODUCTION: The presence of tumor-infiltrating lymphocytes (TILs) is correlated with good prognosis and outcome after (immuno)therapy in triple-negative and HER2-positive breast cancer. However, the role of TILs in luminal breast cancer is less clear. Emerging evidence has now demonstrated that ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobral-Leite, Marcelo, Salomon, Izhar, Opdam, Mark, Kruger, Dinja T., Beelen, Karin J., van der Noort, Vincent, van Vlierberghe, Ronald L. P., Blok, Erik J., Giardiello, Daniele, Sanders, Joyce, Van de Vijver, Koen, Horlings, Hugo M., Kuppen, Peter J. K., Linn, Sabine C., Schmidt, Marjanka K., Kok, Marleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686400/ https://www.ncbi.nlm.nih.gov/pubmed/31391067 http://dx.doi.org/10.1186/s13058-019-1176-2

Ejemplares similares

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
por: Kruger, Dinja T., et al.
Publicado: (2018)

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes
por: Kruger, Dinja T., et al.
Publicado: (2020)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
por: van Rossum, Annelot G.J., et al.
Publicado: (2017)

Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer
por: Blok, Erik J, et al.
Publicado: (2013)

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2021)

Retrospective analysis of metastatic behaviour of breast cancer subtypes
por: Savci-Heijink, C. Dilara, et al.
Publicado: (2015)

A specific gene expression signature for visceral organ metastasis in breast cancer
por: Savci-Heijink, C. D., et al.
Publicado: (2019)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Integration of Clinical and Gene Expression Data Has a Synergetic Effect on Predicting Breast Cancer Outcome
por: van Vliet, Martin H., et al.
Publicado: (2012)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
por: Nederlof, I., et al.
Publicado: (2022)

A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer
por: Krijgsman, Daniëlle, et al.
Publicado: (2019)

Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability
por: van Vliet, Martin H, et al.
Publicado: (2008)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer
por: van wagensveld, lilian, et al.
Publicado: (2023)

Nuclear Localization of CXCR4 Determines Prognosis for Colorectal Cancer Patients
por: Speetjens, Frank M., et al.
Publicado: (2008)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer
por: Reyal, Fabien, et al.
Publicado: (2008)

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
por: Beelen, Karin, et al.
Publicado: (2014)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
por: Kreike, Bas, et al.
Publicado: (2007)

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
por: Nederlof, Iris, et al.
Publicado: (2019)

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer
por: Giardiello, Daniele, et al.
Publicado: (2020)

External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement
por: Hajage, David, et al.
Publicado: (2011)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets
por: Farazi, Thalia A, et al.
Publicado: (2014)

A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer
por: Brandão, Rita D, et al.
Publicado: (2013)

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
por: Kester, Lennart, et al.
Publicado: (2022)

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
por: Holstege, Henne, et al.
Publicado: (2010)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior
por: Savci-Heijink, C. D., et al.
Publicado: (2019)

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
por: Mercan, Caner, et al.
Publicado: (2022)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Sentinel node in ovarian cancer: study protocol for a phase 1 study
por: Kleppe, Marjolein, et al.
Publicado: (2013)

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
por: van de Vijver, Marc J
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_e49e57u7fo538ijssiotn172fi